Antengene Corporation Limited (HK:6996) has released an update.
Antengene Corporation Limited has announced the approval of XPOVIO® as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma in China. This marks a significant milestone for the company, enhancing its portfolio in the realm of hematology oncology treatments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
